Avity Investment Management Inc. Acquires 6,537 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Avity Investment Management increased its Thermo Fisher Scientific stake by 11.5% in the second quarter, acquiring 6,537 shares to hold 63,263 shares valued at approximately $31.7 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 versus the $5.71 consensus and revenue of $11.99 billion. Revenue rose 10.5% year over year, and the company set fiscal 2026 EPS guidance of $24.93–$25.33.
• The stock carries a “Moderate Buy” consensus rating with an average analyst price target of $619.41, while recent insider activity has been negative: executives sold a combined 15,850 shares on August 6 under a Rule 10b5-1 plan.

Avity Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,263 shares of the medical research company's stock after acquiring an additional 6,537 shares during the quarter. Thermo Fisher Scientific makes up about 2.0% of Avity Investment Management Inc.'s portfolio, making the stock its 21st biggest holding. Avity Investment Management Inc.'s holdings in Thermo Fisher Scientific were worth $31,718,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Howard Capital Management Inc. lifted its position in Thermo Fisher Scientific by 0.5% during the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company's stock worth $1,791,000 after acquiring an additional 16 shares during the last quarter. Salomon & Ludwin LLC lifted its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock worth $669,000 after purchasing an additional 17 shares during the last quarter. Elyxium Wealth LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after buying an additional 20 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its stake in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock valued at $1,436,000 after buying an additional 20 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $593.11 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $219.30 billion, a P/E ratio of 31.90, a P/E/G ratio of 2.42 and a beta of 0.85. The business has a 50 day moving average of $517.63 and a 200-day moving average of $510.61.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the company's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president owned 14,784 shares of the company's stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,250 shares of company stock worth $12,235,950 over the last quarter. Company insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMO. Piper Sandler raised their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a "market perform" rating and a $520.00 target price for the company. HSBC downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Barclays boosted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source